Currently, out of the existing stock ratings of Kevin Kedra - 4 which are a Buy (30.77%), 7 which are a Hold (53.85%), 2 which are a Sell (15.38%)

Kevin Kedra

Work Performance Price Targets & Ratings Chart

Analyst Kevin Kedra works at GABELLI and is covering the Healthcare sector with 25 price targets and ratings displayed on 4 stocks.

Kevin Kedra's average stock forecast success ratio is 66.67% with an average time for price targets to be met of 430.67 days.

Most recent stock forecast was given on LXRX, Lexicon Pharmaceuticals at 15-Jan-2021.

Wall Street Analyst Kevin Kedra

Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.

Average potential price target upside

LXRX Lexicon Pharmaceuticals ELAN Elanco Animal Health TTPH PAHC

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

8

$6.84 (589.66%)

3 months 21 days ago

4/16 (25%)

$8.71 (111.98%)

36

Buy

10

$8.84 (762.07%)

10

11 months 18 days ago

0/2 (0%)

$7.19 (261.81%)

Hold

6

$4.84 (417.24%)

3

2 years 6 months 10 days ago

2/5 (40%)

$5.39 (60.47%)

43

Hold

2

$0.84 (72.41%)

38

2 years 7 months 23 days ago

2/9 (22.22%)

$12.67 (82.00%)

409

Hold

7

$5.84 (503.45%)

2 years 7 months 23 days ago

3/3 (100%)

$1.33 (13.05%)

55

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Kevin Kedra?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart